Galmed Pharmaceuticals Ltd GLMD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/14/24 EDT
0.44quote price arrow up+0.0355 (+8.7937%)
Volume
897
Close
0.4037UNCH (UNCH)
Volume
149,167
52 week range
0.26 - 5.63
Loading...
  • Open0.3801
  • Day High0.4392
  • Day Low0.369
  • Prev Close0.3883
  • 52 Week High5.63
  • 52 Week High Date05/22/23
  • 52 Week Low0.26
  • 52 Week Low Date11/21/23

Key Stats

  • Market Cap2.426M
  • Shares Out6.01M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-11.27

KEY STATS

  • Open0.3801
  • Day High0.4392
  • Day Low0.369
  • Prev Close0.3883
  • 52 Week High5.63
  • 52 Week High Date05/22/23
  • 52 Week Low0.26
  • 52 Week Low Date11/21/23
  • Market Cap2.426M
  • Shares Out6.01M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-11.27

RATIOS/PROFITABILITY

  • EPS (TTM)-3.68
  • P/E (TTM)-0.11
  • Fwd P/E (NTM)-1.26
  • EBITDA (TTM)-7.461M
  • ROE (TTM)-50.63%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-821.73%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galmed Pharmaceuticals Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Allen Baharaff
President, Chief Executive Officer, Director
Guy Nehemya
Chief Operating Officer, Data Protection Officer
Doron Cohen
Chief Financial Officer
Yohai Stenzler CPA
Chief Accounting Officer
Address
16 Tiomkin Street
Tel Aviv-yafo
6578317
Israel